NCT02976194

Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy

Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Pusan National University Hospital · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.

Detailed description

PCV is regarded as a subtype of age-related macular degeneration (ARMD), but has several different features such as polypoidal terminal of new vessels, and relative resistance to anti-VEGF treatment. Other cytokines then VEGF are thought to be associated with development and progression of the disease. The aim of the this study is to investigate intraocular cytokines related to recurrence of polypoidal choroidal vasculopathy. Aqueous humor will be sampled from the anterior chamber at baseline, after loading injections of ranibizumab and at recurrence. The concentration of various cytokines will be measured in the aqueous humor.

Conditions

• Exudative Age-related Macular Degeneration
• Polypoidal Choroidal Vasculopathy

Interventions

Type	Name	Description
DRUG	ranibizumab	Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.

Timeline

• Start date: 2016-11-22
• Primary completion: 2019-11-01
• Completion: 2020-01-01
• First posted: 2016-11-29
• Last updated: 2019-10-10

Locations

2 sites across 1 country: South Korea